Type 2 DiabetesRESET2pilotNCT05375695
Feasibility of Time-Restricted Eating in the Treatment of Type 2 Diabetes
A study testing Time-restricted eating in people with Type 2 Diabetes, run by Kristine Færch at 1 site in Denmark.
Trial summary
The overall aim of this pilot study is to examine feasibility of a 12-week 10-hour time-restricted eating intervention in individuals with overweight or obesity and type 2 diabetes. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Type 2 Diabetes
- What is being tested?
- Time-restricted eating
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteDenmark
- Study dates
- 1 Apr 2022to 15 Nov 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age: ≥18 years
- Overweight or obesity (BMI ≥25 kg/m2)
- T2D with HbA1c >53 mmol/mol
- Habitual eating window ≥12 h/day (incl. foods/snacks and energy-containing beverages)
- Associated with the T2D clinic at Steno Diabetes Center Copenhagen (SDCC) or Hvidovre Hospital
Who cannot join
- Weight loss >5kg last 3 months
- Bariatric surgery or planned bariatric surgery within study duration
- Use of fast acting insulin and combination insulin products
- Unable or unwilling to adhere to time-restricted eating; for instance, due to competing medical conditions.
- A wish to adhere to Ramadan
- For women: current/planned pregnancy or lactation
Show all 12Show fewer
- Alcohol or drug abuse (judged by investigator) or treatment with disulfiram
- Severe hypoglycaemia within last year (Severe hypoglycaemia, as defined by the American Diabetes Association, denotes severe cognitive impairment requiring external assistance for recovery)
- Inability to understand written and oral information in Danish.
- Diagnosed with an eating disorder in the past 3 years
- Medical condition which, based on investigators assessment, challenges participation including but not limited to severe heart, vascular or lung disease, cancer, chemotherapy, psychiatric gastrointestinal, rheumatic or endocrine diseases etc.
- Concomitant participation in other intervention study
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Feasibility of Time-Restricted Eating in the Treatment of Type 2 Diabetes - the RESET2 Pilot Study
The overall aim of this pilot study is to examine feasibility of a 12-week 10-hour time-restricted eating intervention in individuals with overweight or obesity and type 2 diabetes. The results of the pilot study will inform recruitment, design and delivery of a future long-term time-restricted randomized controlled trial.
Read the detailed description
In people with type 2 diabetes (T2D), weight loss is associated with improved glycaemic control and markers of cardiometabolic function as well as reduced use of antidiabetic medicine. Beyond pharmacological treatments, current strategies to reduce body weight and improve glycaemia include energy-restricted diets and increased physical activity.
Lifestyle interventions are complex, affecting many aspects of peoples' daily life. Dietary restrictions often result in rapid weight loss, but the weight is gradually regained by many. Barriers to implement and maintain dietary changes include lack of knowledge, support, and insights into the type and amount of foods eaten. Previous lifestyle interventions targeting weight loss in T2D show efficacy for improving markers of metabolic risk, including weight and glycaemia during the intervention, but relapse of behavior and weight regain are often present.
One reason may be that the intervention is not modified according to the needs of the target group. Often, weight loss interventions are shaped by a 'one size fits all' model where both individual capabilities and motivation as well as social and contextual factors are more or less ignored. A user-based design will facilitate enrolment of participants and likely promote uptake and maintenance of the intervention among participants.
Intermittent fasting regimens have been suggested as efficient strategies for improving cardiometabolic health to a greater extent than can be attributed to the reduction in energy intake alone. Time-restricted eating limits the time available for food intake to typically 4-10 hours/day without other dietary restrictions and has been put forward as a novel, acceptable, and safe lifestyle modification and has shown promising effects on body weight, glucose metabolism, appetite, and cardiometabolic health in individuals at high risk of T2D.
The overall aim of this pilot study is to examine feasibility of a 12-week 10-hour time-restricted eating based intervention in individuals with overweight or obesity and T2D. Participants will attend visit 1 (baseline), visit 2 (8 weeks after baseline) and visit 3 (12 weeks after baseline). The study consists of 8 weeks of strict time-restricted eating, followed by 4 weeks of individually adjusted time-restricted eating.
Specific aims are:
- To assess adherence and participants' experiences, needs and barriers with an 8-week strict time-restricted eating period, followed by a 4-week period with an individually adjusted time-restricted eating based intervention
- To examine whether intervention components are delivered by health care professionals as intended
- To explore if intervention support components are acceptable, useful and sufficient for the participants
- To study recruitment processes and retention, and related barriers and facilitators
- To evaluate examination days
- Conditions
- Type 2 Diabetes
- Being tested
- Time-restricted eating
- Keywords
- time-restricted eating, type 2 diabetes, obesity, overweight, fasting, circadian rhythm
- Medical subject headings
- Diabetes Mellitus, Type 2, Intermittent Fasting, Obesity, Overweight, Fasting
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Time-restricted eatingOther
The intervention consists of an 8-week strict time-restricted eating period, where participants follow the same 10-hour eating window (self-selected timing from 6 am to 8 pm) each day with minimal support to obtain lived experiences with challenges associated with time-restricted eating. Followed by an individually adjusted 4-week time-restricted eating period, including supporting components.
Staff will help participants select a time-interval that fits into their daily life. Diet is ad libitum and with no further dietary restrictions. The time-restricted eating intervention is an addition to standard care.
| Study group | Role | What they receive |
|---|---|---|
| Time-restricted eating | Experimental | Time-restricted eating for 12 weeks (n=20). Receives: Other: Time-restricted eating |
What is being measured
The primary outcome is the main question the study is designed to answer.
Adherence (%)
Self-reported adherence to a 10-hour eating window/day during a 8-week strict time-restricted eating period. % compliance = (number of days compliant/total days) * 100%.
Measured: Registered 1 day/week on random days per e-mail from baseline to week 8.
Adherence (%)
Self-reported adherence to a 10-hour eating window during a 4-week individually adjusted time-restricted eating period. % compliance = (number of days compliant/total days) * 100%.
Measured: Registered 1 day/week on random days per e-mail from week 8 to week 12.
Participants' experiences, needs and barriers
Analysis of conversations at visit 2 to assess participants' experiences, needs and barriers with a 8-week strict time-restricted eating period.
Measured: 8 weeks after baseline.
Participants' experiences, needs and barriers
Analysis of interviews at visit 3 to assess participants' experiences, needs and barriers with a 4-week individually adjusted time-restricted eating period, including to explore if intervention support components are acceptable, useful and sufficient for the participants.
Measured: 12 weeks after baseline.
Secondary outcomes (41)
Recruitment process and retention
Registered numbers of: people with interest in the project, people attending pre-screening and screening, included participants, drop-outs and completers.
Measured: Up to 12 weeks.
Evaluation of examination days
Analysis of interviews to evaluate examination days.
Measured: Interviews at baseline and after 8 and 12 weeks.
Fidelity
Assessment of the extent (%) to which the conversations are conducted according to the conversation guidelines. Average score for conversations at baseline and average score for conversations at visit 2 will be calculated.
Measured: Conversations at baseline and after 8 weeks.
Body weight (kg)
Measured on a digital scale. Fasted state at baseline and after 12 weeks, non-fasted state after 8 weeks
Measured: Measured at baseline and after 8 and 12 weeks
Body mass index (kg/m^2)
Calculated from body weight (kg) and height (m). Fasted state at baseline and after 12 weeks, non-fasted state after 8 weeks.
Measured: Measured at baseline and after 8 and 12 weeks.
Fat mass (kg)
Measured by electronical bioimpedance. Fasted state at both visits.
Measured: Measured at baseline and after 12 weeks.
Fat free mass (kg)
Measured by electronical bioimpedance. Fasted state at both visits.
Measured: Measured at baseline and after 12 weeks.
Fat percentage (%)
Measured by electronical bioimpedance. Fasted state at both visits.
Measured: Measured at baseline and after 12 weeks.
Waist circumference (cm)
Measured using tape measure.
Measured: Measured at baseline and after 12 weeks.
Hip circumference (cm)
Measured using tape measure.
Measured: Measured at baseline and after 12 weeks.
HbA1c (mmol/mol and %)
Assessed from blood samples in fasted state.
Measured: Measured at baseline and after 12 weeks.
Systolic blood pressure (mmHg)
Measured under resting and fasting conditions.
Measured: Measured at baseline and after 12 weeks.
Diastolic blood pressure (mmHg)
Measured under resting and fasting conditions.
Measured: Measured at baseline and after 12 weeks.
Heart rate (bpm)
Measured under resting and fasting conditions during measurements of blood pressure.
Measured: Measured at baseline and after 12 weeks.
Metabolites
Fasting concentrations of glucose, cholesterols, triglycerides.
Measured: Measured at baseline and after 12 weeks.
Hormone
Fasting concentration of insulin.
Measured: Measured at baseline and after 12 weeks.
Marker of kidney function - Sodium
Fasting concentration of sodium.
Measured: Measured at baseline and after 12 weeks.
Marker of kidney function - Potassium
Fasting concentration of potassium.
Measured: Measured at baseline and after 12 weeks.
Marker of kidney function - Creatinine
Fasting concentration of creatinine.
Measured: Measured at baseline and after 12 weeks.
Markers of kidney function - eGFR
Estimated glomerular filtration rate (eGFR).
Measured: Measured at baseline and after 12 weeks.
Subjective appetite
Rated using visual analogue scales and includes sensations of: Hunger, fullness, satiety, prospective food consumption, wellbeing, nausea, thirst, desire to eat meat, salty, and sweet. The scale range is 0-100 and each end represent the extremes e.g. hunger rating: "I am not hungry at all" to "I have never been this hungry before".
Measured: Measured at baseline and after 12 weeks.
Food choice
Food choice of food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire. Food choice is determined based on frequency of selection made within each food category. The scores range from 0-48 i.e. 0 = foods within a specific food category have not been selected at all to 48 = foods within a specific food category have been selected 48 times.
Measured: Measured at baseline and after 12 weeks.
Implicit wanting
Implicit wanting of food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire. Implicit wanting is assessed based on food choice and response time for selected and non-selected food items as well as mean response time.
Measured: Measured at baseline and after 12 weeks.
Explicit liking
Explicit liking of 16 food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire. Explicit liking is rated using visual analogue scales and the range is 0-100. Each end represents the extremes e.g. Question: "how pleasant would it be to taste this food right now?" Answer: "not at all" (rated 0 on the 0-100 scale) to "extremely" (rated 100 on the 0-100 scale).
Measured: Measured at baseline and after 12 weeks.
Explicit wanting
Explicit wanting of 16 food items from four combined food categories (high-fat savoury, high-fat sweet, low-fat savoury and low-fat sweet foods) examined from the computerized Leeds Food Preference Questionnaire. Explicit wanting is rated using visual analogue scales and the range is 0-100. Each end represents the extremes e.g. Question: "how much do you want some of this food now?" Answer: "not at all" (rated 0 on the 0-100 scale) to "extremely" (rated 100 on the 0-100 scale).
Measured: Measured at baseline and after 12 weeks.
Self-reported physical activity
Assessed from questionnaire International Physical Activity Questionnaire, and measures health-related physical activity. To calculate MET minutes a week multiply the MET value given by the minutes the activity was carried out and again by the number of days that that activity was undertaken.
Measured: Measured at baseline and after 12 weeks.
Self-reported sleep quality
Assessed from the questionnaire Pittsburgh Sleep Quality Index. The questionnaire consists of 19 items. Each item is weighted on a 0-3 interval scale. The global PSQI score is then calculated by totaling the seven component scores, providing an overall score ranging from 0 to 21, where lower scores denote a healthier sleep quality.
Measured: Measured at baseline and after 12 weeks
Self-reported health and wellbeing
Assessed from the questionnaire Self-reported Health (SF-12 health survey). SF-12 consists of 12 items. Scores range from 0 to 100, with higher scores indicating better physical and mental health functioning. A score of 50 or less on the Physical Component Summary has been recommended as a cut-off to determine a physical condition; while a score of 42 or less on the Mental Component Summary may be indicative of 'clinical depression'.
Measured: Measured at baseline and after 12 weeks.
Self-reported sleepiness
Assessed from the questionnaire the Epworth Sleepiness Scale. The questionnaire consists of 8 questions, which is weighted on a 0-3 interval scale. A low total score can be interpreted as a normal daytime sleepiness, and a higher score as a mild, moderate and severe excessive daytime sleepiness, respectively.
Measured: Measured at baseline and after 12 weeks.
Self-reported chronotype
Assessed from the questionnaire Munich Chronotype Questionnaire (MCTQ). The questionnaire consists of 17 questions to identify type of chronotype. The MCTQ uses the midpoint between sleep on- and offset on free days (mid-sleep on free days) to assess chronotype.
Measured: Measured at baseline and after 12 weeks.
Self-reported food intake
Assessed from questionnaire Food Frequency Questionnaire. The questionnaire collects dietary data and uses a context-specific food list to estimate the usual diet. The questionnaire consists of 15 items with sub questions. Output is total energy intake and macronutrient composition.
Measured: Measured at baseline and after 12 weeks
Self-reported night eating
Assessed from questionnaire The Night Eating Questionnaire. The questionnaire consists of 14 items, that can be rated from 0 to 4. All items except item 13 are summed to obtain a global score. A total score ≥ 25 has been proposed as a lenient threshold for night eating syndrome.
Measured: Measured at baseline and after 12 weeks.
Self-reported eating behavior
Assessed from questionnaire The Dutch Eating Behavior Questionnaire. It consists of 33 items and comprises three scales that measure emotional, external and restrained eating.Items can be rated from 1 (never) to 5 (very often), with higher scores indicating greater endorsement of the eating behavior.
Measured: Measured at baseline and after 12 weeks.
Self-reported control over eating
Assessed from the questionnaire Control over Eating Questionnaire. It comprises 21 items designed to assess the intensity and type of food cravings an individual experiences, as well as subjective sensations of appetite and mood. Each item can be rated from 1 to 5 on a continuous scale. a lower scale. A higher score indicate less control over eating.
Measured: Measured at baseline and after 12 weeks.
Self-reported fatigue/tiredness
Assessed from questionnaire Fatigue Assessment Scale (FAS). The questionnaire consists of 10 items. Each item can be rated from 1 to 5. The total score ranges from 10 to 50. A total FAS score < 22 indicates no fatigue, a score ≥ 22 indicates fatigue.
Measured: Measured at baseline and after 12 weeks.
Self-reported information on social relations and support
Assessed from 8 selected items on social relations and support from The Danish National Health Survey. Item 1-7 provides information on how often a person is in contact with other people (family, husband/wife, partners, friends, neighbors, etc.), and can be rated from 'daily or almost daily', 'once or twice weekly', 'once or twice monthly', 'less than once monthly' to 'never'. Item 8 provides information on whether a person has somebody to talk to if he/she has problems or needs support, and can be rated 'yes, always', 'yes, mostly', 'yes, sometimes', and 'no, never or almost never'.
Measured: Measured at baseline and after 12 weeks.
Self-reported diabetes distress
Assessed from the Problem Areas in Diabetes Scale (PAID-5 scale) comprising five of the emotional-distress questions of the full PAID items. Each item can be rated from 0 to 4. A total score of ≥ 8 indicates possible diabetes related emotional distress.
Measured: Measured at baseline and after 12 weeks.
Self-reported well-being
Assessed from the WHO (Five) Well-being Index. The WHO-5 consists of five statements, which respondents rate from 0 to five (in relation to the past two weeks).The total raw score, ranging from 0 to 25, is multiplied by 4 to give the final score, with 0 representing the worst imaginable well-being and 100 representing the best imaginable well-being.
Measured: Measured at baseline and after 12 weeks
Self-reported diabetes management
Assessed from 9 selected items on diabetes management from the The Danish National Patient Reported Outcome Questionnaire, version 1.05. The items can be rated from 'very sure/confident' to 'not sure/confident at all'.
Measured: Measured at baseline and after 12 weeks.
Sexual satisfaction
Assessed from 1 item on sexual satisfaction from the questionnaire The Danish National Health Survey. The item addresses to which degree a persons sexual needs are covered. The item can be rated from 'to a very high degree' to 'not at all'.
Measured: Measured at baseline and after 12 weeks.
Sexual functioning
Assessed from 4 items on sexual functioning from the Danish National Patient Reported Outcome Questionnaire, version 1.05. Item 1 can be rated 'yes' or 'no'. 'Yes' represents problems with sexual functioning. Item 2-4 can be rated from 'not at all' to 'extreme', where extreme represents problems with sexual functioning.
Measured: Measured at baseline and after 12 weeks.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted17 May 2022
- Study start1 Apr 2022
- Primary completion15 Nov 2022
- Study completion15 Nov 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Type 2 DiabetesStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (actual)
Sponsor and investigators
- Lead sponsor
- Kristine Færch
- Sponsor type
- University, hospital or other
- Collaborators
- Hvidovre University Hospital, University of Leeds, Salk Institute for Biological Studies, University of Copenhagen
- Responsible party
- Sponsor-investigator, Kristine Færch, Steno Diabetes Center Copenhagen
- Investigators
- Kristine Færch, PhD, Principal investigator, Steno Diabetes Center Copenhagen
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05375695
- Sponsor's protocol ID
- H-21041830
- Acronym
- RESET2pilot
- Status last verified
- Nov 2022
- First submitted
- 27 Mar 2022
- Last updated
- 17 Nov 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Publications
Termannsen AD, Bjerre N, Hansen GS, Jalking L, Faerch K, Hempler NF, Quist JS, Varming A. Theory-based process evaluation of a non-randomised single-arm pilot study investigating time-restricted eating in the treatment of type 2 diabetes-the RESET2 pilot study. Pilot Feasibility Stud. 2025 Nov 6;11(1):135. doi: 10.1186/s40814-025-01715-4.
PubMed 41199408
Study at a glance
From the registry record, last updated by the sponsor on 17 Nov 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Feasibility of Time-Restricted Eating in the Treatment of Type 2 Diabetes - the RESET2 Pilot Study
- ClinicalTrials.gov ID
- NCT05375695
- Acronym / sponsor ID
- RESET2pilot / H-21041830
- Conditions
- Type 2 Diabetes
- Keywords
- time-restricted eating, type 2 diabetes, obesity, overweight, fasting, circadian rhythm
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 20 participants (actual)
- Lead sponsor
- Kristine FærchUniversity, hospital or other
- Collaborators
- Hvidovre University Hospital, University of Leeds, Salk Institute for Biological Studies, University of Copenhagen
- Study start
- 1 Apr 2022 (actual)
- Primary completion
- 15 Nov 2022 (actual)
- Study completion
- 15 Nov 2022 (actual)
- First posted
- 17 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overall aim of this pilot study is to examine feasibility of a 12-week 10-hour time-restricted eating intervention in individuals with overweight or obesity and type 2 diabetes. The results of the pilot study will inform recruitment, design and delivery of a future long-term time-restricted randomized controlled trial.
Detailed description
In people with type 2 diabetes (T2D), weight loss is associated with improved glycaemic control and markers of cardiometabolic function as well as reduced use of antidiabetic medicine. Beyond pharmacological treatments, current strategies to reduce body weight and improve glycaemia include energy-restricted diets and increased physical activity.
Lifestyle interventions are complex, affecting many aspects of peoples' daily life. Dietary restrictions often result in rapid weight loss, but the weight is gradually regained by many. Barriers to implement and maintain dietary changes include lack of knowledge, support, and insights into the type and amount of foods eaten. Previous lifestyle interventions targeting weight loss in T2D show efficacy for improving markers of metabolic risk, including weight and glycaemia during the intervention, but relapse of behavior and weight regain are often present.
One reason may be that the intervention is not modified according to the needs of the target group. Often, weight loss interventions are shaped by a 'one size fits all' model where both individual capabilities and motivation as well as social and contextual factors are more or less ignored. A user-based design will facilitate enrolment of participants and likely promote uptake and maintenance of the intervention among participants.
Intermittent fasting regimens have been suggested as efficient strategies for improving cardiometabolic health to a greater extent than can be attributed to the reduction in energy intake alone. Time-restricted eating limits the time available for food intake to typically 4-10 hours/day without other dietary restrictions and has been put forward as a novel, acceptable, and safe lifestyle modification and has shown promising effects on body weight, glucose metabolism, appetite, and cardiometabolic health in individuals at high risk of T2D.
The overall aim of this pilot study is to examine feasibility of a 12-week 10-hour time-restricted eating based intervention in individuals with overweight or obesity and T2D. Participants will attend visit 1 (baseline), visit 2 (8 weeks after baseline) and visit 3 (12 weeks after baseline). The study consists of 8 weeks of strict time-restricted eating, followed by 4 weeks of individually adjusted time-restricted eating.
Specific aims are:
- To assess adherence and participants' experiences, needs and barriers with an 8-week strict time-restricted eating period, followed by a 4-week period with an individually adjusted time-restricted eating based intervention
- To examine whether intervention components are delivered by health care professionals as intended
- To explore if intervention support components are acceptable, useful and sufficient for the participants
- To study recruitment processes and retention, and related barriers and facilitators
- To evaluate examination days
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Time-restricted eating | Experimental | Other: Time-restricted eatingTime-restricted eating for 12 weeks (n=20). |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Age: ≥18 years
- Overweight or obesity (BMI ≥25 kg/m2)
- T2D with HbA1c >53 mmol/mol
- Habitual eating window ≥12 h/day (incl. foods/snacks and energy-containing beverages)
- Associated with the T2D clinic at Steno Diabetes Center Copenhagen (SDCC) or Hvidovre Hospital
Key exclusion criteria (12 listed)
- Weight loss >5kg last 3 months
- Bariatric surgery or planned bariatric surgery within study duration
- Use of fast acting insulin and combination insulin products
- Unable or unwilling to adhere to time-restricted eating; for instance, due to competing medical conditions.
- A wish to adhere to Ramadan
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Time-restricted eatingThe intervention consists of an 8-week strict time-restricted eating period, where participants follow the same 10-hour eating window (self-selected timing from 6 am to 8 pm) each day with minimal support to obtain lived experiences with challenges associated with time-restricted eating. Followed by an individually adjusted 4-week time-restricted eating period, including supporting components. Staff will help participants select a time-interval that fits into their daily life. Diet is ad libitum and with no further dietary restrictions. The time-restricted eating intervention is an addition to standard care. | Other | Time-restricted eating |
Primary outcome
Adherence (%)
Time frame: Registered 1 day/week on random days per e-mail from baseline to week 8.
Self-reported adherence to a 10-hour eating window/day during a 8-week strict time-restricted eating period. % compliance = (number of days compliant/total days) * 100%.
Adherence (%)
Time frame: Registered 1 day/week on random days per e-mail from week 8 to week 12.
Self-reported adherence to a 10-hour eating window during a 4-week individually adjusted time-restricted eating period. % compliance = (number of days compliant/total days) * 100%.
Participants' experiences, needs and barriers
Time frame: 8 weeks after baseline.
Analysis of conversations at visit 2 to assess participants' experiences, needs and barriers with a 8-week strict time-restricted eating period.
Participants' experiences, needs and barriers
Time frame: 12 weeks after baseline.
Analysis of interviews at visit 3 to assess participants' experiences, needs and barriers with a 4-week individually adjusted time-restricted eating period, including to explore if intervention support components are acceptable, useful and sufficient for the participants.
41 secondary outcomes
Recruitment process and retention
Time frame: Up to 12 weeks.
Evaluation of examination days
Time frame: Interviews at baseline and after 8 and 12 weeks.
Fidelity
Time frame: Conversations at baseline and after 8 weeks.
Body weight (kg)
Time frame: Measured at baseline and after 8 and 12 weeks
Body mass index (kg/m^2)
Time frame: Measured at baseline and after 8 and 12 weeks.
Fat mass (kg)
Time frame: Measured at baseline and after 12 weeks.
Fat free mass (kg)
Time frame: Measured at baseline and after 12 weeks.
Fat percentage (%)
Time frame: Measured at baseline and after 12 weeks.
Waist circumference (cm)
Time frame: Measured at baseline and after 12 weeks.
Hip circumference (cm)
Time frame: Measured at baseline and after 12 weeks.
HbA1c (mmol/mol and %)
Time frame: Measured at baseline and after 12 weeks.
Systolic blood pressure (mmHg)
Time frame: Measured at baseline and after 12 weeks.
Diastolic blood pressure (mmHg)
Time frame: Measured at baseline and after 12 weeks.
Heart rate (bpm)
Time frame: Measured at baseline and after 12 weeks.
Metabolites
Time frame: Measured at baseline and after 12 weeks.
Hormone
Time frame: Measured at baseline and after 12 weeks.
Marker of kidney function - Sodium
Time frame: Measured at baseline and after 12 weeks.
Marker of kidney function - Potassium
Time frame: Measured at baseline and after 12 weeks.
Marker of kidney function - Creatinine
Time frame: Measured at baseline and after 12 weeks.
Markers of kidney function - eGFR
Time frame: Measured at baseline and after 12 weeks.
Subjective appetite
Time frame: Measured at baseline and after 12 weeks.
Food choice
Time frame: Measured at baseline and after 12 weeks.
Implicit wanting
Time frame: Measured at baseline and after 12 weeks.
Explicit liking
Time frame: Measured at baseline and after 12 weeks.
Explicit wanting
Time frame: Measured at baseline and after 12 weeks.
Self-reported physical activity
Time frame: Measured at baseline and after 12 weeks.
Self-reported sleep quality
Time frame: Measured at baseline and after 12 weeks
Self-reported health and wellbeing
Time frame: Measured at baseline and after 12 weeks.
Self-reported sleepiness
Time frame: Measured at baseline and after 12 weeks.
Self-reported chronotype
Time frame: Measured at baseline and after 12 weeks.
Self-reported food intake
Time frame: Measured at baseline and after 12 weeks
Self-reported night eating
Time frame: Measured at baseline and after 12 weeks.
Self-reported eating behavior
Time frame: Measured at baseline and after 12 weeks.
Self-reported control over eating
Time frame: Measured at baseline and after 12 weeks.
Self-reported fatigue/tiredness
Time frame: Measured at baseline and after 12 weeks.
Self-reported information on social relations and support
Time frame: Measured at baseline and after 12 weeks.
Self-reported diabetes distress
Time frame: Measured at baseline and after 12 weeks.
Self-reported well-being
Time frame: Measured at baseline and after 12 weeks
Self-reported diabetes management
Time frame: Measured at baseline and after 12 weeks.
Sexual satisfaction
Time frame: Measured at baseline and after 12 weeks.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 17 Nov 2022.
- Derived from this study: PubMed 41199408Termannsen AD, Bjerre N, Hansen GS, Jalking L, Faerch K, Hempler NF, Quist JS, Varming A. Theory-based process evaluation of a non-randomised single-arm pilot study investigating time-restricted eating in the treatment of type 2 diabetes-the RESET2 pilot study. Pilot Feasibility Stud. 2025 Nov 6;11(1):135. doi: 10.1186/s40814-025-01715-4.
- Individual participant dataSharing planned: No
Related trials for Type 2 Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Not yet recruitingPhase 3
A Study to Evaluate the Effectiveness and Safety of the Drug AZD6234 for Managing Weight in Adults Who Are Obese or Overweight. These Participants May or May Not Also Have Type 2 Diabetes
Obesity, Overweight
Not yet recruiting
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D)
Type 2 Diabetes Mellitus (T2D), Obesity (BMI>30)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kristine Færch, PhD principal investigator
Steno Diabetes Center Copenhagen
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Time-restricted eating in people with Type 2 Diabetes, run by Kristine Færch at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 17 Nov 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Adherence (%) (time frame: Registered 1 day/week on random days per e-mail from baseline to week 8.). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05375695, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Nov 2022.